title: [Efficacy of 5-nitroimidazole derivatives in treatment of bacterial vaginosis].
abstract: OBJECTIVE
  To evaluate the efficacy and adverse effects of 5-nitroimidazole derivatives in treatment of bacterial vaginosis (BV).
  
  
  METHODS
  278 BV patients were randomly divided into 8 groups to be treated with (1) oral metronidazole sustained release tablet 750 mg/day for 7 days, (2) oral metronidazole sustained release tablet 750 mg/day for 7 days and vaginal tinidazole 250 mg for 7 days, (3) oral tinidazole 1 g/day for 3 days (2 g for the first dose), (4) oral tinidazole 1 g/day for 3 days (2 g for the first dose), (5) oral ornidazole 2 x 500 mg/day for 3 days and vaginal tinidazole 250 mg for 7 days, (6) oral ornidazole 2 x 500 mg/day for 3 days, (7) oral secnidazole 2 g in a single dose and vaginal tinidazole 250 mg for 7 days, and (8) oral secnidazole 2 g in a single dose.
  
  
  RESULTS
  The clinical cure rates of the oral administration groups were 56.76% - 62.50%, all significantly lower than those of the oral/vaginal combination groups (80.00% - 86.11%, all P < 0.05). There was nit significantly difference in efficacy level among the only oral treatment groups and the oral/vaginal combination groups (all P > 0.05).
  
  
  CONCLUSIONS
  Combination of oral and vaginal administration of 5-nitroimidazole derivatives is more effective in treatment of BV than oral administration only.
authors.affiliation: Department of Pharmacy, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.
authors.forename: Feng-Mei
authors.initials: FM
authors.lastname: Wang
authors.forename: Xiao-Dan
authors.initials: XD
authors.lastname: Qian
authors.forename: Hong
authors.initials: H
authors.lastname: Xu
authors.forename: He-Yong
authors.initials: HY
authors.lastname: Yu
mesh_terms: D000282:Administration, Intravaginal; D000284:Administration, Oral; D000328:Adult; D003692:Delayed-Action Preparations; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008795:Metronidazole / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009593:Nitroimidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D009950:Ornidazole / Q000008:administration & dosage / Q000627:therapeutic use*; D011446:Prospective Studies; D013607:Tablets; D014011:Tinidazole / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome; D016585:Vaginosis, Bacterial / Q000188:drug therapy*; D055815:Young Adult
chemical_list: D003692:Delayed-Action Preparations; D009593:Nitroimidazoles; D013607:Tablets; D014011:Tinidazole; D008795:Metronidazole; D009950:Ornidazole; C016724:secnidazole